Covid-19 roundup: Study suggests AstraZeneca/Oxford booster is effective against variants — report; IFPMA issues guidance on vaccine inequity
As Covid-19 variants continue to emerge and spread, scientists are already thinking about shots to boost the efficacy of the first wave of vaccines — including the adenovirus-based jab developed by Oxford University and AstraZeneca. An unnamed source told the Financial Times that a third dose of that vaccine can “blow through almost any variant.”
A recent study shows promise for a third dose of the AstraZeneca/Oxford shot to protect against new variants, sources familiar with the trial data told the FT. One went so far as to call the antibody reaction “unbelievable.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.